Majda Hadziahmetovic, MD
Ophthalmology · Durham, NCNPI 1972853695
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,023 of the $36,695 with a category attached, or 60.0%. 13 manufacturers reported payments, led by Ocular Therapeutix, Inc. at 33.5% of the total. 2025 is the largest year on record at $11,709, more than ten times the $236 reported in 2019. Among ophthalmology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 44 payments — averaging $833.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$12K
- Bausch & Lomb Americas Inc.$9K
- AbbVie$8K
- Astellas Pharma US Inc$7K
- Genentech USA, Inc.$283
- Regeneron$233
- plus $1K from 7 others
Across 11 payments — averaging $218,972 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$2.3M
- Apellis Pharmaceuticals, Inc.$112K
What the payments were for
- Consulting fees$22,02360%
- Travel & lodging$1,3314%
- Food & beverage$3,3419%
- Education$10,00027%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ocular Therapeutix, Inc. | 5 | $12,293 |
| Bausch & Lomb Americas Inc. | 8 | $8,554 |
| AbbVie | 12 | $7,716 |
| Astellas Pharma US Inc | 4 | $6,565 |
| Genentech USA, Inc. | 1 | $283 |
| Regeneron | 2 | $233 |
| Genentech, Inc. | 2 | $203 |
| Alimera Sciences, Inc. | 2 | $174 |
| Alcon | 1 | $150 |
| Notal Vision, Inc. | 2 | $143 |
| Apellis Pharmaceuticals, Inc. | 2 | $140 |
| Neurotech Pharmaceuticals, Inc. | 2 | $129 |
| Regeneron Healthcare Solutions, Inc. | 1 | $111 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,695 in reported general payments places this provider in the 95th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 21 | $22,048 |
| Prednisolone Acetate | 56 | $1,837 |
| Ketorolac Tromethamine | 41 | $912 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 37 | $539 |
| ErythromycinErythromycin Base | 21 | $240 |
| Brimonidine Tartrate | 19 | $161 |
| Latanoprost | 20 | $93 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $7,716 | $22,04821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 588 ophthalmology providers in North Carolina.
Other ophthalmology in Durham
- Julie WoodwardDurham$1M
- Lejla VajzovicDurham$681K
- Terry KimDurham$605K
- Leon HerndonDurham$230K
- Glenn JaffeDurham$218K
- Robin VannDurham$213K
- Anthony KuoDurham$186K
- Michael RichardDurham$113K
- Priyatham MettuDurham$111K
- Jason LissDurham$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.